African-Led Vaccine Initiative Secures $16.5M to Fight Record Ebola Outbreak

CAIRO, Egypt – August 27, 2026 – In a significant move that intertwines global health finance with regional industrial strategy, the Coalition for Epidemic Preparedness Innovations (CEPI) has committed up to US$16.5 million to an Egyptian-led effort to develop a vaccine against the Bundibugyo ebolavirus. The funding will back Minapharm Group, a leading African biopharmaceutical company, as it advances a promising vaccine candidate designed to combat the fastest-growing Ebola outbreak on record, currently devastating the Democratic Republic of the Congo (DRC).

This partnership is more than a financial transaction; it represents a strategic investment in a new model of global health security—one where technological innovation and manufacturing capacity are cultivated within Africa, for Africa. As the world confronts a viral threat with no licensed vaccines or treatments, this initiative is a critical test of whether regional self-sufficiency can become the backbone of a more resilient global response architecture.

A Crisis Unfolding with Unprecedented Speed

The urgency of this investment cannot be overstated. Since the WHO declared a Public Health Emergency of International Concern on May 17, 2026, the Bundibugyo virus has carved a deadly path through the DRC. As of last week, official figures reported a staggering 5,584 confirmed cases and 2,680 deaths, resulting in a case fatality rate of 48%. The outbreak surpassed 1,000 confirmed cases in just 40 days, a terrifying velocity that dwarfs the 235 days it took the 2018 Zaire ebolavirus outbreak to reach the same grim milestone. This is now, unequivocally, the largest and deadliest Ebola outbreak the country has ever faced.

The virus is spreading across six provinces against a complex backdrop of regional insecurity, highly mobile populations, and strained health infrastructure. These factors have severely hampered traditional public health responses like contact tracing and have contributed to the rapid escalation of the crisis. With no approved countermeasures, frontline health workers are left with only supportive care, making the race for a vaccine a matter of life and death for thousands.

A Diversified Bet on Technology

CEPI’s strategy is not to place a single bet, but to build a diversified portfolio of vaccine technologies to maximize the chances of success. Minapharm’s candidate is the fifth to receive funding, joining a global effort that includes mRNA platforms from Moderna, ChAdOx adenovirus vectors from the University of Oxford and Serum Institute of India, and rVSV technologies from IAVI. This portfolio approach is a financial and scientific hedge against the high failure rate inherent in vaccine development.

What makes the Minapharm candidate a crucial addition is its underlying technology: the MVA-CR19 platform. Developed by ProBioGen, Minapharm’s Berlin-based subsidiary, this platform uses a Modified Vaccinia Ankara (MVA) vector—a highly attenuated and safe strain of the virus used in licensed smallpox and mpox vaccines. Its key distinction is its design to induce both B-cell (antibody) and T-cell (cellular) immune responses. This two-pronged attack could offer more comprehensive and long-lasting immunity, a critical feature for protecting populations against a persistent threat.

"ProBioGen's MVA-CR19 platform was developed to enable rapid generation of recombinant MVA vaccine candidates and scalable manufacturing," said Dr. Volker Sandig, Chief Scientific Officer of ProBioGen. "We are proud to bring this platform and our CMC expertise to a Minapharm-led programme supported by CEPI, helping advance a Bundibugyo ebolavirus vaccine candidate towards clinical evaluation in response to an urgent public-health need."

Forging Health Sovereignty in Africa

Beyond the immediate crisis, this partnership is a landmark event in the continent's push for health sovereignty. The funding from CEPI enables a powerful synergy: German-engineered technology will be brought to life by African manufacturing prowess. Initially, ProBioGen will produce the core drug substance in Germany, which will then be shipped to Minapharm's state-of-the-art facility in Cairo for final formulation and packaging. The strategic roadmap, however, aims for a full technology transfer, enabling end-to-end manufacturing—from cell line to finished vial—on Egyptian soil.

This vision of localized production is a direct response to the lessons of past health crises, where dependency on global supply chains left many nations vulnerable. Dr. Wafik Bardissi, Chairman and CEO of Minapharm, framed the initiative as a culmination of decades of building regional capacity. "With CEPI's support, we are turning scientific ingenuity into health sovereignty, drawing on the breadth of our technologies and know-how to advance a vaccine response for Africa," he stated.

This sentiment was echoed by Dr. Jean Kaseya, Director General of the Africa CDC, who emphasized the strategic importance of this capability. "A vaccine candidate advanced by an African company is exactly the kind of capability our continent needs - not just for this outbreak, but so that Africa can develop and manufacture the tools it needs to protect its own people," Dr. Kaseya said. This project is a tangible step toward the Africa CDC's goal of building a resilient, self-reliant public health ecosystem.

The Financial Architecture of Epidemic Response

The CEPI-Minapharm deal exemplifies the modern financial architecture required to combat pandemics. CEPI, an innovative partnership of public, private, and philanthropic organizations, acts as a global catalyst, directing capital toward the most promising scientific endeavors to meet its '100 Days Mission'—developing a vaccine against a new threat within 100 days. The funding for this project is sourced from a coalition including the European Commission and the U.S. Department of State, demonstrating a shared global commitment.

"CEPI's funding to Minapharm harnesses the growing strength of African-led innovation to help confront this increasingly severe outbreak and prepare for future threats," said Dr. Richard Hatchett, CEO of CEPI. He described the new candidate as giving the world "another shot on goal" in a high-stakes race.

The path forward involves advancing the vaccine through preclinical studies and into a Phase 1 clinical trial, which will be conducted in Africa. If successful, CEPI is prepared to support late-stage trials needed for emergency use authorization. Critically, all partners are committed to ensuring that if the vaccine proves safe and effective, it will be made rapidly and affordably available to the populations who need it most.